Abiomed (NSDQ:ABMD) has won a one-year reprieve from a proposed 27% Medicare reimbursement cut to hospitals for the use of its Impella ventricular support device. In April, the Centers for Medicare & Medicaid Services (CMS) floated the rate cut proposal for inpatient surgeries involving external assist devices inserted into the heart, such as Impella. The […]
Abiomed stock keeps on sliding
Abiomed (NSDQ:ABMD) shares continued to plummet today following a tough earnings report, closing down -26.45% to $204.87 each. The Danvers, Mass.-based medical device maker reported fiscal first-quarter sales that missed the mark and lowered its top-line outlook on the rest of the year. Abiomed posted profits of $88.9 million, or $1.93 per share, on sales […]
Abiomed plunges on fiscal Q1 earnings miss, lowered outlook
Abiomed (NSDQ:ABMD) shares came under pressure today after the medical device maker reported fiscal first-quarter sales that missed the mark and lowered its top-line outlook on the rest of the year. Danvers, Mass.-based Abiomed posted profits of $88.9 million, or $1.93 per share, on sales of $207.7 million for the three months ended June 3o, […]
Report: “Unglamorous” medtech outshines biopharma in 2019
Medtech merger and acquisition deal announcements slowed in the first half of 2019, but the industry got a boost from Verily’s $1 billion round of funding — the largest ever for a medtech firm. The Verily round was twice the size of the biggest-ever VC deal for a biotech company, according to the Vantage Half-Year […]
FDA: Survival rates still low for Impella RP patients outside narrow patient selection criteria
The FDA today updated data from a post-approval study of Abiomed‘s (NSDQ:ABMD) Impella RP heart pump system, reporting a new 30-day survival rate of 28.6% for patients post-explant, hospital discharge or the start of longer term therapy. A total of 12 of the 42 patients enrolled in the post-market trial of the Danvers, Mass.-based medtech […]
Abiomed launches Impella CP SmartAssist platform
Abiomed (NSDQ:ABMD) said today it is launching its Impella CP with SmartAssist, which won FDA approval last March. The launch will begin alongside the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions which begins on Sunday, the Danvers, Mass.-based company said. The Impella CP with SmartAssist features improvements intended to simplify patient management, integrate clinical data […]
Abiomed wins expanded, 14-day indication for Impella pumps
Abiomed (NSDQ:ABMD) said today that it won an expanded indication from the FDA for two of its Impella heart pumps, extending their indwell times from six to 14 days. The federal safety watchdog’s decision affects the Impella 5.0 and Impella LD devices used to treat cardiogenic shock, Danvers, Mass.-based Abiomed said. The company won the […]
Ex-Abiomed exec looks to keep wrongful termination suit alive
A former Asia VP for Abiomed (NSDQ:ABMD) is hoping to keep a wrongful termination lawsuit alive in a U.S. federal appeals court. In January Keisuke Suzuki lost a lawsuit seeking $2.1 million in damages for unfair termination and denial of an options deal tied to Japanese approval of Abiomed’s Impella heart pump. The Danvers, Mass.-based company […]
Abiomed wins FDA nod for STEMI Impella trial, sees shares drop on Q4 sales miss
Abiomed (NSDQ:ABMD) said today that the FDA approved the launch of a trial exploring its Impella CP Heart pump’s ability to treat patients undergoing treatment for a STEMI heart attack, and saw shares drop after releasing fourth quarter and full year fiscal 2019 earnings that missed sales expectations on Wall Street. The Danvers, Mass.-based company said […]
Abiomed’s stake in Shockwave is worth at least $58m
The $10 million Abiomed (NSDQ:ABMD) put into Shockwave Medical (NSDQ:SWAV) has paid off so far no matter how you slice it. Shockwave raised nearly $97 million in an initial public offering earlier this month, inking a private-placement deal with Abiomed on the side for $10.0 million worth of SWAV shares at the $17-per-share IPO price. […]
ACC 2019 Roundup: Abiomed Impella RP post-market study shows benefit in select patient group
Abiomed (NSDQ:ABMD) today released 18-month post-approval study data from patients treated with its Impella RP, touting a benefit to survival for specifically selected “Recover Right” protocol patients. Results from the study were presented at the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans, the Danvers, Mass.-based company said. The review follows a release […]
- 1
- 2
- 3
- …
- 24
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube